The emergence and rapid spread outside of monkeypox virus (MPXV) to non-endemic areas has led to another global health emergency in the midst of the COVID-19 pandemic. The scientific community has sought to rapidly develop and models that could be applied in research with MPXV. models include two-dimensional (2D) cultures of immortalized cell lines or primary cells and three-dimensional (3D) cultures. models are considered cost-effective and can be done in highly controlled conditions; however, they do not always resemble physiological conditions. In this way, several models are being characterized to meet the growing demand for new studies related to MPXV. In this review, we summarize the main MPXV models that have already been developed and discuss how they can contribute to advance the understanding of its pathogenesis, replication, and transmission, as well as identifying antivirals to treat infected patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712139 | PMC |
| http://dx.doi.org/10.1016/j.isci.2022.105702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-Component Protein Vaccine Induces a Strong and Long-Term Immune Response Against Monkeypox Virus.
Vaccines (Basel)
December 2024
State Key Laboratory of Pathogens and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China.
Background/objectives: Since 2022, outbreaks of monkeypox have raised widespread concern and have been declared a public health emergency of international concern by the World Health Organization. There is an urgent need to develop a safe and effective vaccine against the monkeypox virus (MPXV). Recombinant protein vaccines play a significant role in the prevention of infectious diseases due to their high safety and efficacy.
View Article and Find Full Text PDFLong-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice.
J Med Virol
January 2025
Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
The outbreak of clade II monkeypox virus (MPXV) and the additional outbreak in Central Africa of clade I virus from 2023 have attracted worldwide attention. The development of a scalable and effective vaccine against the ongoing epidemic of mpox is urgently needed. We previously constructed two bivalent MPXV mRNA vaccines, LBA (B6R-A29L) and LAM (A35R-M1R), and a quadrivalent mRNA vaccine, LBAAM (B6R-A35R-A29L-M1R).
View Article and Find Full Text PDFMonkeypox: A comprehensive review on mutation, transmission, pathophysiology, and therapeutics.
Int Immunopharmacol
December 2024
School of Chemical and Biomolecular Engineering, Pusan National University, Busan, South Korea. Electronic address:
Monkeypox virus (MPXV) is the causative agent of the monkeypox (Mpox) disease, belongs to the Orthopoxvirus genus of the Poxviridae family. Due to the recent re-emergence of Mpox in 2024, this is the second time when the World Health Organization (WHO) declared Mpox as a Public Health Emergency of International Concern (PHEIC). This review intends to offer an in-depth analysis of Mpox, including its key characteristics, epidemiological, mutation, pathophysiology, transmission, and therapeutics.
View Article and Find Full Text PDFA penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates.
Nat Commun
December 2024
State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
The recent worldwide outbreaks of mpox prioritize the development of a safe and effective mRNA vaccine. The contemporary mpox virus (MPXV) exhibits changing virological and epidemiological features, notably affecting populations already vulnerable to human immunodeficiency virus (HIV). Herein, we profile the immunogenicity of AR-MPXV5, a penta-component mRNA vaccine targeting five specific proteins (M1R, E8L, A29L, A35R, and B6R) from the representative contemporary MPXV clade II strain, in both naive and simian immunodeficiency virus (SIV)-infected nonhuman primates.
View Article and Find Full Text PDFCrystal structure of F10 core protein from Mpox virus reveals its potential inhibitors.
Int J Biol Macromol
January 2025
Department of Cardiology, the First hospital of Shanxi Medical University, and Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, China; Guangxi Key Laboratory of Precision Medicine for Genetic Diseases, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. Electronic address:
Article Synopsis
- Mpox virus (MPXV) is a rare zoonotic disease that has resulted in over 15,600 cases and 537 deaths to date.
- The study focuses on the RNA polymerase (RNAP) of MPXV, which is crucial for early transcription, and reveals the high-resolution crystal structure of the F10 core protein, which stabilizes essential components of the RNAP complex.
- The research identified a cavity in the RNAP structure and screened 28 potential inhibitors, marking a significant step towards developing treatments for MPXV and similar emerging pathogens.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!